Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Cubicin (daptomycin, legacy) — Worldwide sales by Year
Cubicin (daptomycin, legacy) — Worldwide sales ($M) ($M)
Merck Cubicin (daptomycin, legacy) — Worldwide sales: $152M in FY2020, down 40.9% from a year earlier. No newer figure appears in the documents we track.
Where the FY2020 figure comes from
“|| Cubicin | 46 | 32 | 39 | 36 | 152 | 88 | 67 | 52 | 50 | 257 | -27 | -28 | -41 | -40”
Source: Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cubicin (daptomycin, legacy) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2020 | Dec 31, 2020 | 152 | -40.9% | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2019 | Dec 31, 2019 | 257 | -30.0% | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2018 | Dec 31, 2018 | 367 | -3.9% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2017 | Dec 31, 2017 | 382 | -64.9% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2016 | Dec 31, 2016 | 1,087 | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Breakdown
What makes up cubicin (daptomycin, legacy) — Worldwide sales
- Cubicin (daptomycin, legacy) — U.S. sales ($M)46 · FY2020
- Cubicin (daptomycin, legacy) — International sales ($M)106 · FY2020
- Cubicin (daptomycin, legacy) — Worldwide reported growth YoY (%)-41.0% · FY2020
- Cubicin (daptomycin, legacy) — Worldwide constant-currency (ex-exchange) growth YoY (%)-40.0% · FY2020
Cite this data
StockData. (2026). Merck Cubicin (daptomycin, legacy) — Worldwide sales ($M), annual FY2016–FY2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-cubicin
See every metric in the Merck KPI table. Data updated Oct 26, 2026.